Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers

AM Chapman, KY Sun, P Ruestow, DM Cowan… - Lung cancer, 2016 - Elsevier
Lung cancer is the leading cause of cancer-related mortality. While the majority of lung
cancers are associated with tobacco smoke, approximately 10–15% of US lung cancers …

Comparison of gefitinib, erlotinib and afatinib in non‐small cell lung cancer: a meta‐analysis

Z Yang, A Hackshaw, Q Feng, X Fu… - … journal of cancer, 2017 - Wiley Online Library
Gefitinib, erlotinib and afatinib are three widely used epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non‐small cell lung cancer …

Effectiveness of tyrosine kinase inhibitors on “uncommon” epidermal growth factor receptor mutations of unknown clinical significance in non–small cell lung cancer

JY Wu, CJ Yu, YC Chang, CH Yang, JY Shih… - Clinical cancer …, 2011 - AACR
Purpose: Clinical features of epidermal growth factor receptor (EGFR) mutations, L858R,
deletions in exon 19, T790M, and insertions in exon 20, in non–small cell lung cancer …

Tumor microenvironment: a new treatment target for cancer

MJ Tsai, WA Chang, MS Huang… - International Scholarly …, 2014 - Wiley Online Library
Recent advances in cancer therapy encounter a bottleneck. Relapsing/recurrent disease
almost always developed eventually with resistance to the initially effective drugs. Tumor …

Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors

M Juchum, M Günther, SA Laufer - Drug Resistance Updates, 2015 - Elsevier
Multiple mutations in the EGFR gene are a major cause for the failure of Erlotinib and
Gefitinib in the treatment of patients harboring non-small-cell lung cancer (NSCLC) who …

Epidermal growth factor receptor‐tyrosine kinase inhibitor therapy is effective as first‐line treatment of advanced non‐small‐cell lung cancer with mutated EGFR: a …

G Gao, S Ren, A Li, J Xu, Q Xu, C Su… - … journal of cancer, 2012 - Wiley Online Library
Gefiinib and erlotinib are two similar small molecules of selective and reversible epidermal
growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs), which have been approved …

CircRNAs and lung cancer: biomarkers and master regulators

X Di, X Jin, R Li, M Zhao, K Wang - Life sciences, 2019 - Elsevier
CircRNAs are a class of competitive, endogenous, non-coding RNAs with closed-loop
structures. High-throughput sequencing indicates that circRNAs are ubiquitously expressed …

Lung injury and lung cancer caused by cigarette smoke-induced oxidative stress: Molecular mechanisms and therapeutic opportunities involving the ceramide …

T Goldkorn, S Filosto, S Chung - Antioxidants & redox signaling, 2014 - liebertpub.com
Chronic obstructive pulmonary disease (COPD) and lung cancer are frequently caused by
tobacco smoking. However, these diseases present opposite phenotypes involving redox …

[HTML][HTML] Current approaches in NSCLC targeting K-RAS and EGFR

V Aran, J Omerovic - International journal of molecular sciences, 2019 - mdpi.com
The research and treatment of non-small cell lung cancer (NSCLC) have achieved some
important advances in recent years. Nonetheless, the overall survival rates for NSCLC …

Effectiveness of treatments for advanced non–small-cell lung cancer with exon 20 insertion epidermal growth factor receptor mutations

JY Wu, CJ Yu, JY Shih - Clinical lung cancer, 2019 - Elsevier
Background Two main categories of epidermal growth factor receptor (EGFR) mutations in
non–small-cell lung cancer (NSCLC) patients are deletions in exon 19 and L858R in exon …